tetano
Editor, Senior Moderator
Can Commun Dis Rep
. 2021 Nov 10;47(11):461-465.
doi: 10.14745/ccdr.v47i11a03.
Multisystem inflammatory syndrome in children in Canada
Meghan Laverty[SUP] 1 [/SUP], Marina Salvadori[SUP] 1 [/SUP], Susan G Squires[SUP] 1 [/SUP], May Ahmed[SUP] 2 [/SUP], Lisa Eisenbeis[SUP] 3 [/SUP], Santina Lee[SUP] 4 [/SUP], Annick Des Cormiers[SUP] 5 [/SUP], Y Anita Li[SUP] 1 [/SUP]
Affiliations
Abstract
This article provides a summary of the epidemiology of multisystem inflammatory syndrome in children (MIS-C) cases reported nationally in Canada by provincial and territorial health authorities. Multisystem inflammatory syndrome in children is a post-viral inflammatory syndrome that temporally follows coronavirus disease 2019 (COVID-19). Symptoms may include fever, abdominal pain, vomiting, diarrhea, skin rash and other signs of inflammation. In Canada, MIS-C is rare, with 269 cases reported to the Public Health Agency of Canada between March 11, 2020 and October 2, 2021. One hundred forty-two (53%) of these cases were lab-confirmed COVID-19 cases or epidemiologically-linked with COVID-19 cases. Cases have been reported in infants as young as one week to youth as old as 18 years, with a median age of six years. Cases were more likely to occur in males than females (58% vs 42%, respectively; p=0.006). Almost all MIS-C cases (99%) required hospitalization and 36% required intensive care unit admission. No deaths have been reported to date. The time trend of MIS-C aligns with the incidence rate time trend of COVID-19 reported in children, with a two to six-week lag.
Keywords: COVID-19; MIS-C; children’s health; inflammatory syndrome; surveillance.
. 2021 Nov 10;47(11):461-465.
doi: 10.14745/ccdr.v47i11a03.
Multisystem inflammatory syndrome in children in Canada
Meghan Laverty[SUP] 1 [/SUP], Marina Salvadori[SUP] 1 [/SUP], Susan G Squires[SUP] 1 [/SUP], May Ahmed[SUP] 2 [/SUP], Lisa Eisenbeis[SUP] 3 [/SUP], Santina Lee[SUP] 4 [/SUP], Annick Des Cormiers[SUP] 5 [/SUP], Y Anita Li[SUP] 1 [/SUP]
Affiliations
- PMID: 35356073
- PMCID: PMC8896683
- DOI: 10.14745/ccdr.v47i11a03
Abstract
This article provides a summary of the epidemiology of multisystem inflammatory syndrome in children (MIS-C) cases reported nationally in Canada by provincial and territorial health authorities. Multisystem inflammatory syndrome in children is a post-viral inflammatory syndrome that temporally follows coronavirus disease 2019 (COVID-19). Symptoms may include fever, abdominal pain, vomiting, diarrhea, skin rash and other signs of inflammation. In Canada, MIS-C is rare, with 269 cases reported to the Public Health Agency of Canada between March 11, 2020 and October 2, 2021. One hundred forty-two (53%) of these cases were lab-confirmed COVID-19 cases or epidemiologically-linked with COVID-19 cases. Cases have been reported in infants as young as one week to youth as old as 18 years, with a median age of six years. Cases were more likely to occur in males than females (58% vs 42%, respectively; p=0.006). Almost all MIS-C cases (99%) required hospitalization and 36% required intensive care unit admission. No deaths have been reported to date. The time trend of MIS-C aligns with the incidence rate time trend of COVID-19 reported in children, with a two to six-week lag.
Keywords: COVID-19; MIS-C; children’s health; inflammatory syndrome; surveillance.